Skip to main content

Participate in a Trial

Start your journey

NCT03805789 | Phase 2 | Interventional

Acute-graft-versus-host Disease

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

20 Sites
310 Participants
12 Years
NCT04262284 | Observational

Alpha-1 Antitrypsin Deficiency

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

10 Sites
60 Participants
18 Years
NCT03744910 | Phase 3 | Interventional

Antibody-mediated Rejection

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

100 Sites
350 Participants
18 Years to 75 Years
NCT05452317 | Observational

Antibody-mediated Rejection in Kidney Transplant

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

5 Sites
50 Participants
18 Years
NCT04082754 | Phase 1 | Interventional


A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

3 Sites
82 Participants
18 Years to 65 Years
NCT04672733 | Observational

Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

16 Sites
100 Participants
18 Years
NCT05460234 | Observational

Chronic Kidney Disease

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients

4 Sites
500 Participants
18 Years
NCT04044690 | Phase 3 | Interventional


A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

52 Sites
126 Participants
18 Years
NCT04167514 | Phase 3 | Interventional

Graft Versus Host Disease (GVHD)

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

25 Sites
136 Participants
12 Years
NCT05086575 | Observational

Haemophilia B

Observatory of Patients With Haemophilia B Treated by IdElvion®

24 Sites
100 Participants
NCT04864795 | Observational

Heart Failure

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

85 Sites
5000 Participants
18 Years
NCT05130970 | Phase 2 | Interventional

Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

38 Sites
80 Participants
40 Years
NCT04446000 | Phase 1 | Interventional

Immune Complex-mediated Autoimmune Diseases

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

1 Sites
60 Participants
18 Years to 55 Years
NCT04643587 | Phase 1 | Interventional

Noncystic Fibrosis Bronchiectasis (NCFB)

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

3 Sites
64 Participants
18 Years
NCT03684018 | Phase 4 | Interventional

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Two Dose Levels of Privigen in Pediatric CIDP

9 Sites
30 Participants
2 Years to 17 Years
NCT04817670 | Phase 2 | Interventional

Sickle Cell Disease

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

12 Sites
24 Participants
18 Years to 60 Years
NCT04285827 | Phase 1 | Interventional

Sickle Cell Disease

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

13 Sites
32 Participants
18 Years to 60 Years